Intravenous Iron Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

The Global Intravenous Iron Drugs Market is anticipated to expand from USD 2.55 billion in 2025 to USD 3.57 billion by 2031, reflecting a compound annual growth rate (CAGR) of 5.77%. Administered directly into the bloodstream, intravenous (IV) iron therapies are designed to combat iron deficiency and iron deficiency anemia, especially for patients who cannot tolerate oral iron, suffer from malabsorption, or need rapid iron restoration. Market growth is primarily fueled by the rising worldwide incidence of chronic kidney disease, inflammatory bowel disease, and anemias linked to cancer. Furthermore, an aging global population more prone to iron deficiencies amplifies this need. Highlighting the substantial patient base, the World Health Organization's Global Anaemia estimates (2025 Edition) reported that 30.7% of women between 15 and 49 years old experienced anemia in 2023.

Despite these growth drivers, a major obstacle hindering market expansion is the steep expense tied to the development and production of these sophisticated intravenous treatments. This financial barrier could restrict their broad implementation across various healthcare systems.

Market Driver

The Global intravenous iron drugs market is primarily propelled by the drawbacks and poor tolerability of oral iron treatments. Because many individuals suffer from gastrointestinal side effects, they often fail to adhere to or completely abandon oral therapies. Additionally, medical conditions such as chronic kidney disease, inflammatory bowel disease, and previous bariatric surgeries can severely limit oral iron absorption, rendering it useless. The urgent demand for quick iron restoration in severe anemia or acute situations also drives the need for IV delivery. Highlighting this shift, data from the December 2025 American Society of Hematology (ASH) Annual Meeting and Exposition revealed that a multidisciplinary initiative resulted in a 20-fold increase in IV iron infusions for pregnant women over a single year, underlining the strong preference for more effective alternatives when oral treatments fail.

Simultaneously, the market is growing due to continuous improvements in IV iron formulations that deliver greater patient convenience, quicker infusion rates, and enhanced safety. Drug manufacturers are diligently creating advanced products featuring lowered immunogenic risks and refined pharmacokinetics, which allow for larger single doses and less frequent treatments. Such breakthroughs resolve past issues like lengthy infusion times and allergic reactions. Illustrating this progress, CSL's August 2025 Annual Report noted that CSL Vifor was gearing up for more than 30 product rollouts within its nephrology and iron sectors, indicating a robust developmental pipeline. Prioritizing these enhanced therapies remains essential to combatting widespread iron deficiency, as the WHO's 2025 Global Anaemia estimates indicated that 35.5% of pregnant women aged 15 to 49 were anemic in 2023.

Market Challenge

A major hurdle slowing the expansion of the global intravenous iron drugs market is the steep expense involved in the creation and production of these modern therapies. These complex medications require massive financial investments at every stage of their lifecycle, spanning early-stage research and comprehensive clinical trials to rigorous regulatory clearances and highly specialized manufacturing techniques. Ultimately, these heavy financial requirements result in higher prices for the final commercial products.

Such premium pricing severely restricts the broad utilization of IV iron medications, especially in healthcare networks facing tight budgets or strict reimbursement limitations. Demonstrating the scale of industry investments that drive up final drug prices, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) forecasts that worldwide pharmaceutical research and development spending will surpass USD 200 billion in 2025. As a result, a large number of patients are denied access to these vital treatments, which directly suppresses the market's overall growth potential even as the worldwide incidence of iron deficiency and associated anemias continues to climb.

Market Trends

A prominent trend within the global intravenous iron drugs market is the transition toward administering treatments in home-based and outpatient settings. This movement is largely motivated by a growing patient desire for convenience, fewer hospital trips, and the possibility of decreasing medical expenses through decentralized healthcare. The shift is additionally supported by progress in portable infusion technology and the creation of drug formulations that permit rapid, high-dose administrations, allowing a greater number of patients to undergo iron restoration away from conventional clinical facilities.

At the same time, the rising prevalence of affordable generic IV iron options and biosimilars marks another major industry development. The availability of these budget-friendly substitutes heightens market competition, which ultimately drives down medication costs and broadens therapeutic access for a larger demographic. Highlighting this impact, Fierce Pharma reported in February 2026 that industry leader CSL recorded $1.1 billion in asset impairments for fiscal year 2026, driven in part by escalating generic rivalry against its Venofer iron replacement therapy. Such competitive dynamics are vital for healthcare networks striving to control drug spending without compromising patient access to crucial therapies.

Key Market Players

• AMAG pharmaceuticals, Inc.
• Vifor Pharma Management Ltd.
• Daiichi Sankyo Company, Limited
• Rockwell Medical Inc.
• Allergan PLC
• Pfizer Inc.
• Nippon Shinyaku Co.
• Novartis International AG
• Takeda Pharmaceutical Company Limited
• Bausch Health Companies Inc.

Report Scope

In this report, the Global Intravenous Iron Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Intravenous Iron Drugs Market, By Product:

• Iron Dextran
• Ferric Gluconate
• Iron Sucrose
• Ferric Carboxymaltos
• Iron Isomaltoside 1000
• Ferumoxytol

Intravenous Iron Drugs Market, By Application:

• Intestinal Malabsorption Syndromes
• Inflammatory Diseases
• Gastrectomy/Bariatric Surgery
• Anemia
• Osier-Weber-Rendu Disease
• Angiodysplasia
• Pregnancy
• Others

Intravenous Iron Drugs Market, By Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Intravenous Iron Drugs Market.

Available Customizations

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.